New Leaf Venture Partners Research
Investment Thesis
New Leaf Venture Partners (NLVP) is a New York-based venture capital firm exclusively focused on healthcare technology. Formed in 2005 when its healthcare team spun out of the Sprout Group, NLVP believes the healthcare industry is ripe for disruption and partners with exceptional entrepreneurs building tomorrow's leading-edge healthcare businesses. The firm's approach is science- and data-driven, particularly in biopharmaceuticals, and it leans on decades of operating and investing experience across the entire healthcare ecosystem to help portfolio teams navigate industry complexity. NLVP has managed healthcare technology portfolios across four Sprout funds and four New Leaf funds (NLV I through NLV IV, plus multiple Opportunities funds).
Sector Focus
NLVP invests exclusively within three healthcare sub-sectors:
- Biopharmaceuticals — novel therapeutics from company creation through IPO and beyond, with an emphasis on large unmet medical needs, strong science, differentiated technology, and rigorous pre-clinical/clinical data.
- Information Convergence — healthcare IT, diagnostics, and information-based products, including hospital workflow software, care coordination, patient engagement, and drug-cost transparency platforms.
- Life Science Tools — research tools that accelerate drug discovery, uncover disease biology, or personalize diagnosis and treatment.
Stage Focus
NLVP invests across the full healthcare technology lifecycle — from company creation and early venture rounds through growth-stage private financings and into the public markets. It maintains both dedicated venture vehicles and vehicles for private/public growth-stage biopharmaceutical investments (its Opportunities funds).
Check Size
No specific check-size range is published on the firm's website; historical fund vehicles include NLV I–IV and multiple Opportunities funds, suggesting flexible check sizes scaling from early venture rounds to larger growth and public-market positions. Exact figures were not confidently determined from public sources and are therefore left unspecified.
Lead Tendency
NLVP frequently leads or co-leads rounds and takes board seats in its portfolio companies. Team bios list numerous board seats (e.g., BrightInsight, Flosonics Medical, Bluesight, Truveris, CuraSen, Qlaris Bio, Rallybio) alongside several board-observer roles, indicating an active, hands-on ownership style typical of a lead investor.
Recent Activity
NLVP remains actively engaged with its portfolio through 2026. Recent portfolio news includes Rallybio's merger with Avenzo Therapeutics and a concurrent $215M private placement (June 2026), Edgewise Therapeutics' sale of Sevasemten for up to $2.65B (June 2026), Cleerly's continued clinical and payer validation (Aetna coverage approval, MemorialCare adoption, INVICTUS registry data), Bluesight's launch of its Prism AI platform (May 2026), Electra Therapeutics dosing its first patient in a Phase 1 study of ipsoprubart (May 2026), and Star Therapeutics receiving FDA Rare Pediatric Disease and Breakthrough Therapy designations (April 2026). Third-party trackers also cite newer financings including BrightInsight (Jan 2026) and Electra Therapeutics Series C (Oct 2025).
Portfolio Highlights
NLVP's portfolio spans dozens of companies across its three focus sectors. Notable current holdings include Arvinas (NASDAQ: ARVN), Edgewise Therapeutics (NASDAQ: EWTX), Cogent Biosciences (NASDAQ: COGT), Rallybio, Cleerly, BrightInsight, TigerConnect, Bluesight (formerly Kit Check), Kalderos, Flosonics Medical, Star Therapeutics, Electra Therapeutics, and Qlaris Bio. Notable exits/acquisitions include Dice Therapeutics (acquired by Eli Lilly), Advanced Cell Diagnostics (acquired by Bio-Techne), Audax Health (acquired by Optum/UnitedHealth), QPID Health (acquired by eviCore), ePocrates (acquired by athenahealth), Pharsight (acquired by Tripos), Phase Forward (acquired by Oracle), and legacy Sprout-era exits such as Relypsa (Vifor Pharma), Harpoon Therapeutics (Merck), Sierra Oncology (GSK), Stromedix (Biogen Idec), and Aspreva Pharmaceuticals (Galenica Group).
Team
- Ron Hunt, Co-Founder/Managing Director (New York) — Focuses on early- to late-stage biopharmaceutical investments; one of the founders of New Leaf in 2005.
- Vijay Lathi, Co-Founder/Managing Director (Menlo Park) — Focuses on information convergence and diagnostics; joined Sprout in 1998, promoted to Partner in 2003, co-founded New Leaf in 2005; founding investor in Ilypsa (sold to Amgen) and Relypsa (RLYP); MIT/Stanford, B.S./M.S. Chemical Engineering.
- Craig Slutzkin, COO/CFO (New York) — Manages finance, operations, compliance, and HR; joined Sprout Group in 2002 as CFO and was part of the 2005 spin-out to form New Leaf; MBA from Columbia, CPA.
Decision Process
The firm operates as a small, senior partnership (two co-founder Managing Directors plus a COO/CFO), consistent with a partnership-style decision process rather than a solo-GP or large investment-committee structure.
Founder Preferences
NLVP looks for capable teams solving real healthcare problems in unique, scientifically rigorous ways — experienced management teams with novel product programs, well-differentiated technology, and (in biopharma) strong pre-clinical/clinical data.
Geographic Focus
Primarily United States (New York and the Bay Area, where its two Managing Directors are based), with selective international investments (e.g., ReViral in the United Kingdom, Saniona in Denmark).